SQZ Biotechnologies Announces $2 Million Grant From the National Institutes of Health to Develop a Novel, Scalable Cell Replacement Therapy for Parkinson’s Disease
SQZ Biotechnologies has received a $2 million SBIR Phase II grant from the National Institute of General Medical Sciences to develop methods for reprogramming immune cells into dopamine-producing neurons. This innovative approach aims to offer a new treatment paradigm for Parkinson's disease, potentially eliminating the need for chronic immunosuppression. The company's proprietary Cell Squeeze technology may enable efficient cell engineering with significant therapeutic potential beyond Parkinson's, targeting conditions like Multiple Sclerosis and Type 1 diabetes.
- Awarded $2 million SBIR Phase II grant from National Institute of General Medical Sciences.
- Potential to create dopamine-producing neurons could revolutionize Parkinson's disease treatment.
- Utilization of patient's immune cells may reduce the need for chronic immunosuppression.
- Cell Squeeze technology allows for efficient and flexible cell engineering.
- None.
Project to Focus on Creating Dopamine-Producing Neurons Using Direct mRNA-based Reprogramming of Immune Cells
“Directly creating dopamine-producing neurons by reprogramming a patient’s own immune cells would be a major breakthrough and could support a new Parkinson’s disease treatment paradigm,” said
Reprogramming a patient’s cells to replace lost or diseased cells has significant therapeutic potential. Beyond Parkinson’s Disease, applications for cell replacement therapies include Multiple Sclerosis and Type 1 diabetes. However, traditional expensive, time-intensive, and inefficient cell reprogramming methods has hindered clinical progress and patient impact.
At the 2021
With the support of the
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements relating to events our platform development, our product candidates, project funding, preclinical and clinical activities, progress and outcomes, development plans, manufacturing, clinical safety and efficacy results, therapeutic potential, market opportunities and disease prevalence. These forward-looking statements are based on management's current expectations. Actual results could differ from those projected in any forward-looking statements due to several risk factors. Such factors include, among others, risks and uncertainties related to our limited operating history; our significant losses incurred since inception and expectation to incur significant additional losses for the foreseeable future; the development of our initial product candidates, upon which our business is highly dependent; the impact of the COVID-19 pandemic on our operations and clinical activities; our need for additional funding and our cash runway; the lengthy, expensive, and uncertain process of clinical drug development, including uncertain outcomes of clinical trials and potential delays in regulatory approval; our ability to maintain our relationships with our third party vendors and strategic collaborators; and protection of our proprietary technology, intellectual property portfolio and the confidentiality of our trade secrets. These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K, as updated by our Quarterly Report on Form 10-Q for the quarterly period ended
Certain information contained in this press release relates to or is based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this press release, we have not independently verified, and we make no representation as to the adequacy, fairness, accuracy or completeness of any information obtained from third-party sources.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220321005152/en/
SQZ
Media
781-392-5514
john.lacey@sqzbiotech.com
Investors
857-760-0398
michael.kaiser@sqzbiotech.com
Source:
FAQ
What was the recent grant awarded to SQZ Biotechnologies?
How will the grant impact SQZ Biotechnologies' research?
What is the significance of the Cell Squeeze technology for SQZ?
What potential treatments could arise from SQZ's research?